Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995137 | 0.93 | MEN1 (0.48) | CHEK1DGAT1CYP11B1CYP11B2 | |
| SCHEMBL5003465 | 0.93 | MEN1 (0.48) | CHEK1DGAT1CYP11B1CYP11B2 | |
| SCHEMBL4996226 | 0.93 | CHEK1 (0.48) | CHEK1PIM2RAD52 | |
| SCHEMBL4996260 | 0.93 | CHEK1 (0.48) | CHEK1PIM2 | |
| SCHEMBL5000847 | 0.93 | CHEK1 (0.46) | CHEK1DGAT1CLK2CLK3DYRK1A | |
| SCHEMBL4992090 | 0.91 | ALDH1A1 (0.48) | CHEK1DGAT1CLK2CLK3DYRK1A | |
| SCHEMBL4991463 | 0.91 | CHEK1 (0.45) | CHEK1DGAT1CLK2CLK3DYRK1A | |
| SCHEMBL4991478 | 0.90 | CHEK1 (0.43) | CHEK1DGAT1CLK2CLK3DYRK1A | |
| SCHEMBL4993709 | 0.90 | PIM1 (0.49) | CHEK1DGAT1DHFRCYP11B1CYP11B2 | |
| SCHEMBL4993330 | 0.89 | CHEK1 (0.57) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | CHEK1 1668/4885DGAT1 4877/4885CLK2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.